Press release
Organon & Co. (NYSE: OGN) Investor Alert: Deadline in Lawsuit on July 22, 2025
A Deadline is coming up on July 22, 2025 in the lawsuit for certain investors in Organon & Co. (NYSE: OGN).
Investors who purchased shares of Organon & Co. (NYSE: OGN) have certain options and there are strict and short deadlines running. Deadline: July 22, 2025. NYSE: OGN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of Organon & Co. (NYSE: OGN) common shares between October 31, 2024, to April 30, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 31, 2024, to April 30, 2025, the Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the Company's priorities, particularly, related to capital allocation through quarterly dividends, and that the Defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.
Those who purchased shares of Organon & Co. (NYSE: OGN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Organon & Co. (NYSE: OGN) Investor Alert: Deadline in Lawsuit on July 22, 2025 here
News-ID: 4108927 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Nutex Health Inc. (NAS …
An investor, who purchased shares of Nutex Health Inc. (NASDAQ: NUTX), filed a lawsuit over alleged violations of Federal Securities Laws by Nutex Health Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Nutex Health Inc. (NASDAQ: NUTX) have certain options and for certain investors are short and strict deadlines running. Deadline: October 21, 2025. NASDAQ: NUTX investors should contact the Shareholders Foundation at…
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investor Alert: Deadline in Lawsuit o …
A deadline is coming up on September 15, 2025 in the lawsuit filed for certain investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) over alleged securities laws violations by Capricor Therapeutics, Inc.
Investors who purchased shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) have certain options and there are strict and short deadlines running. Deadline: September 15, 2025. Capricor Therapeutics, Inc. (NASDAQ: CAPR) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Investigation announced for Long-Term Investors in shares of Tempus AI, Inc. (NA …
An investigation was announced for current long-term investors in shares of Tempus AI, Inc. (NASDAQ: TEM) concerning potential breaches of fiduciary duties by certain directors and officers of Tempus AI, Inc..
Investors who are current long term investors in Tempus AI, Inc. (NASDAQ: TEM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
RxSight, Inc. (NASDAQ: RXST) Investor Alert: Deadline in Lawsuit on September 22 …
A deadline is coming up on September 22, 2025 in the lawsuit filed for certain investors of RxSight, Inc. (NASDAQ: RXST) over alleged securities laws violations by RxSight, Inc.
Investors who purchased shares of RxSight, Inc. (NASDAQ: RXST) have certain options and there are strict and short deadlines running. Deadline: September 22, 2025. RxSight, Inc. (NASDAQ: RXST) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Organon
Hypogonadism Pipeline | Clinical Trials, Key Companies -Mereo BioPharma, Merck, …
DelveInsight's, "Hypogonadism- Pipeline Insight, 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hypogonadism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download the Sample Report to learn more
@https://www.delveinsight.com/sample-request/hypogonadism-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Hypogonadism Overview
Hypogonadism occurs when your sex…
Muscle Relaxant Monitor Market | Blink Device, GE, IDMED, Organon Laboratories
The global muscle relaxant monitor market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the muscle relaxant monitor market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Mirtazapine Tablets Market Analysis & Trends - Industry Forecast to 2027 |Novart …
LOS ANGELES, United States: The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global Mirtazapine Tablets market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Mirtazapine Tablets market. The authors of the report have segmented the global Mirtazapine Tablets market as per…
Mirtazapine Tablets Market To Witness Huge Growth By 20277- Novartis, Mylan, Org …
Complete study of the global Mirtazapine Tablets market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Mirtazapine Tablets industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also…
Ethinylestradiol Market Trend, Size, Share, Forecast 2021-2027 | Organon, Bayer, …
Ethinylestradiol market Research Report
LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, “Global Ethinylestradiol Market Report, History and Forecast 2016-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application“. This report offers an insightful take on the drivers and restraints present in the market. Ethinylestradiol data reports also provide a 5 year pre-historic and forecast for the sector and include data on socio-economic data…
Werum Dispensing System for Organon Ireland
Werum MES software PAS-WD manages weighing processes
Lueneburg, Germany, July 18, 2007 - At its Swords site located to the north of Dublin, Organon Ireland has implemented a new weighing and dispensing system from Werum. The new system based on Werum\'s PAS-WD product has replaced an existing system self developed by Organon.
The key objective of the new automated dispensing system is to manage the weighing of ingredients (actives,…
